Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)34.00
  • Today's Change-0.05 / -0.15%
  • Shares traded220.00
  • 1 Year change-12.82%
  • Beta0.3768
Data delayed at least 15 minutes, as of Apr 24 2024 09:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.

  • Revenue in EUR (TTM)517.36m
  • Net income in EUR47.62m
  • Incorporated1967
  • Employees2.81k
  • Location
    Boiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
  • Phone+33 478456100
  • Fax+33 478456291
  • Websitehttps://www.boiron.fr/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Guerbet SA785.69m23.87m445.60m2.92k19.601.185.350.56711.801.8062.1529.970.79970.59835.80269,071.902.261.402.961.8678.0176.022.821.821.215.620.503557.824.30-0.0993158.05-12.615.23-10.07
Pharma Mar SA158.15m1.14m506.60m509.00492.152.5273.423.200.05610.05618.8210.970.43110.28685.56310,713.200.309918.520.420725.8993.9293.760.718928.872.22--0.1842---19.457.77-97.70--46.37--
Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS233.91m13.04m510.05m622.0039.103.6724.752.181.521.5227.1716.121.166.537.7213,105,500.006.4512.398.9117.5322.0719.065.556.950.9854--0.2095---23.3847.18-28.97147.97----
Calliditas Therapeutics AB104.29m-40.29m516.92m181.00--16.09--4.96-8.69-8.6922.496.240.63325.028.776,667,895.00-24.46-26.46-30.27-30.2794.99---38.63-76.593.08-4.440.7427--50.32---13.08------
Valneva SE153.71m-101.43m518.11m684.00--4.03--3.37-0.7343-0.73431.110.9240.28432.544.69224,726.60-18.76-15.39-31.44-25.0634.3735.94-65.99-34.951.37-3.570.6195---57.466.3429.21--35.18--
Pharmanutra SpA100.20m12.83m521.80m105.0040.399.5334.675.211.331.3310.415.660.94260.36484.90954,304.8012.0718.3916.1224.8097.5696.3612.8117.771.8357.610.339952.5121.1316.51-14.738.4475.7111.20
Philogen SpA23.13m-6.16m533.68m160.00--8.12--23.07-0.1551-0.15510.57472.250.18876.657.95144,562.50-5.03-7.32-5.56-8.3640.0432.04-26.64-58.666.84--0.1414---2.4610.80-14.60--51.78--
Basilea Pharmaceutica AG Allschwil161.54m10.71m553.82m147.0047.06--44.853.430.87650.876513.15-0.83350.79991.065.161,072,340.005.30-1.867.69-2.9983.0083.456.63-2.992.642.021.10--6.683.53-13.96--11.17--
Boiron SA517.36m47.62m597.42m2.81k12.421.079.051.152.742.7429.7931.730.67921.366.57184,705.806.145.087.566.3973.8875.129.047.402.54--0.022548.8717.36-2.8656.44-10.60-19.01-7.22
Pharming Group N.V.229.29m-9.86m606.78m415.00--2.97120.732.65-0.0162-0.01620.3490.30470.55210.50896.65552,504.80-2.375.26-2.816.6389.7289.41-4.309.263.33-4.000.4395--19.309.01-177.14---13.04--
Gubra A/S27.48m-5.97m642.20m219.00--9.95--23.37-2.91-2.9113.5129.44------936,095.90--------56.06---21.72------0.1296--2.82---1,133.04------
Puretech Health PLC10.97m-43.94m663.65m111.00--1.48--60.49-0.1336-0.13360.03331.430.0155--3.6384,951.40-5.165.21-5.906.53-----333.47265.77---34.790.04790.00-10.1843.8616.85--0.046--
Surgical Science Sweden AB76.29m20.22m665.83m260.0032.911.7726.618.734.594.5917.3285.160.18881.876.153,395,585.005.004.495.314.7869.4270.0626.5023.753.56--0.000.0010.0168.1424.47--38.57--
Formycon AG68.64m-42.24m690.38m224.00--1.47--10.06-2.80-2.804.4126.650.07991.542.24334,839.00-4.863.03-5.173.2935.5231.61-61.5310.911.00--0.02020.0016.077.86370.82--120.72--
Data as of Apr 24 2024. Currency figures normalised to Boiron SA's reporting currency: Euro EUR

Institutional shareholders

5.66%Per cent of shares held by top holders
HolderShares% Held
Financi�re de l'�chiquier SAas of 31 Mar 2023464.46k2.65%
The Vanguard Group, Inc.as of 05 Apr 2024138.93k0.79%
Dimensional Fund Advisors LPas of 04 Apr 202483.74k0.48%
SMA Gestion SAas of 30 Jun 202176.17k0.43%
Sycomore Asset Management SAas of 31 Jan 202469.77k0.40%
Norges Bank Investment Managementas of 31 Dec 202347.88k0.27%
HC Capital Advisors GmbHas of 30 Jun 202338.51k0.22%
Gay-Lussac Gestion SAas of 31 Dec 202232.50k0.19%
Amplegest SASas of 31 Aug 202324.91k0.14%
Chaussier Gestion SAas of 28 Mar 202417.00k0.10%
More ▼
Data from 30 Jun 2021 - 28 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.